All Oncology News

No new safety signals were identified, and imAEs were predominantly low-grade and consistent with the known durvalumab safety profile.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

The PD-1/antiangiogenic combination yielded a 24% ORR and 28-month median PFS, surpassing prior monotherapy benchmarks in refractory chordoma.

Adding lutetium Lu 177 vipivotide tetraxetan to ADT and ARPI deepened PSA responses and reduced the risk of PSA progression by 58% in patients with mHSPC.

Talazoparib plus enzalutamide data show rPFS correlates moderate-to-strongly with OS in first-line mCRPC across biomarker-defined subgroups.

Enzalutamide plus leuprolide produced a median treatment suspension of 17 months vs 11.5 months with leuprolide alone in biochemically recurrent prostate cancer.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.

A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.

The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.

Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.

The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.

TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff.

Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.

Beth N. McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.

AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.

Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.

Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.

The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.

A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.

Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.